Welcome to LookChem.com Sign In|Join Free
  • or

1110813-31-4

Post Buying Request

1110813-31-4 Suppliers

Recommended suppliersmore

Product FOB Price Min.Order Supply Ability Supplier
Factory supply Dacomitinib 99.8%
Cas No: 1110813-31-4
USD $ 90.0-100.0 / Metric Ton 1 Metric Ton 10 Metric Ton/Day Toda Biotechnology Co., Limited. Contact Supplier
Dacomitinib
Cas No: 1110813-31-4
No Data No Data 5 Kilogram/Day Shanghai Innopharm Industrial Co.,Ltd Contact Supplier
Dacomitinib
Cas No: 1110813-31-4
No Data No Data No Data Chemwill Asia Co., Ltd. Contact Supplier
Factory Price API 99% Dacomitinib (PF299804) 1110813-31-4 GMP Manufacturer
Cas No: 1110813-31-4
USD $ 0.1-0.1 / Gram 1 Gram 100 Metric Ton/Year Xi'an Xszo Chem Co., Ltd. Contact Supplier
Dacomitinib
Cas No: 1110813-31-4
No Data 10 Milligram Amadis Chemical Co., Ltd. Contact Supplier
Dacomitinib Manufacturer/High quality/Best price/In stock
Cas No: 1110813-31-4
USD $ 1.0-1.0 / Gram 1 Gram 5 Metric Ton/Month Anhui Dexinjia Biopharm Co., Ltd Contact Supplier
DACOMITINIB(PF299804)
Cas No: 1110813-31-4
USD $ 3.0-3.0 / Kilogram 1 Kilogram 1-100 Metric Ton/Month Dayang Chem (Hangzhou) Co.,Ltd. Contact Supplier
Dacomitinib
Cas No: 1110813-31-4
USD $ 100.0-100.0 / Gram 1000 Gram 10 Metric Ton/Month Hebei yanxi chemical co.,LTD. Contact Supplier
Dacomitinib?(PF299804) /factory price/99%50KG in stock
Cas No: 1110813-31-4
USD $ 1.0-1.0 / Kilogram 1 Kilogram 100 Kilogram/Month Shenzhen Tianyuan Pharmaceutical Technology Co., Ltd Contact Supplier
Dacomitinib (PF299804) CAS NO 1110813-31-4
Cas No: 1110813-31-4
No Data 1 Kilogram 20000 Kilogram/Day Hubei XinRunde Chemical Co., Ltd Contact Supplier

1110813-31-4 Usage

Description

Dacomitinib is a selective and irreversible inhibitor of EGFR. It is a drug candidate for the treatment of non-small cell lung carcinoma. It is current under the Phase III clinical trials. It also shows potential for the treatment of HER-2 amplified breast cancer cells lines that are resistant to trastuzumab and lapatinib.

Biological activity

Dacomitibib (Dacomitinib, PF299804) is an effective and irreversible pan-ErbB inhibitor that is most effective in EGFR, with an IC50 of 6 nM. It is also highly effective in NSCLCs that carries EGFR or ERBB2 mutants (against Gefitinib) and EGFR T790M mutant. Phase 2. Dacomitinib is taken orally once-daily. It is an irreversible inhibitor of HER-1 (EGFR), HER-2 and HER-4 tyrosine kinases. Dacomitinib targets multiple receptors of the HER pathway, whereas currently marketed HER-1 (EGFR) inhibitors for non-small cell lung cancer (NSCLC) target only one receptor in this pathway,developed by Pfizer.

Definition

ChEBI: A member of the class of quinazolines that is 7-methoxyquinazoline-4,6-diamine in which the amino group at position 4 is substituted by a 3-chloro-4-fluorophenyl group and the amino group at position 6 is substituted by an (E)-4-(piperidin 1-yl)but-2-enoyl group.

Clinical Study

Dacomitinib has advanced to several Phase III clinical trials. The results of the first trials were disappointing, with a failure to meet the study goals, Additional Phase III trials are ongoing. Clinical evaluation of dacomitinib is ongoing in a number of clinical trials in patients with advanced NSCLC across lines of therapies and a range of histologies and molecular subtypes, such as EGFR and KRAS status. Additionally, there is an ongoing clinical trial evaluating dacomitinib in recurrent and/or metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN).

Uses

PF299804 is a potent, irreversible pan-ErbB inhibitor against ErbB1, ErbB2 and ErbB4 with IC50 of 6 nM, 45.7 nM and 73.7 nM, respectively.

Uses

Dacomitinib (PF299804), which name is (E)-N-[4-(3-chloro-4-fluoroanilino)-7- methoxyquinazolin-6-yl]-4-piperidin-1-ylbut-2-enamide, is a potent, orally available, highly selective, irreversible small-molecule tyrosine kinase inhibitor (TKI) of tyrosine kinase human epidermal growth factor receptors (HER) 1 (EGFR), HER2, and HER4. It is most effective against EGFR with IC50 of 6 nM. It is highly effective against NSCLCs carrying EGFR or ERBB2 mutant (anti-Gefitinib) and EGFR T790M mutant.
InChI:InChI=1S/C24H25ClFN5O2/c1-33-22-14-20-17(24(28-15-27-20)29-16-7-8-19(26)18(25)12-16)13-21(22)30-23(32)6-5-11-31-9-3-2-4-10-31/h5-8,12-15H,2-4,9-11H2,1H3,(H,30,32)(H,27,28,29)/b6-5+

1110813-31-4SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 17, 2017

Revision Date: Aug 17, 2017

1.Identification

1.1 GHS Product identifier

Product name Dacomitinib

1.2 Other means of identification

Product number -
Other names Dacomitinib [USAN]

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:1110813-31-4 SDS

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1110813-31-4